DRUG
To Assess Safety and Efficacy of Bolus Versus Continuous Infusion of Terlipressin in Acute Variceal Bleeding
Status
Completed
Phase
Not applicable
Enrollment
110
Locations
1
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
The study is single centered; prospective, parallel arm randomized controlled trial.The patients will be who presented to Institute of Liver \& Biliary Sciences with esophageal variceal bleeding or develop esophageal bleeding during hospital stay. All patients will be managed with continuous non-invasive cardiac and hemodynamic monitoring including cardiac rhythm, pulse rate, blood pressure, and oxygen saturation. Hemoglobin (Hb) will checked every 6 h for the initial 48 h and then every 12 h till discharge. Likewise, serum creatinine will checked daily. Packed red blood cells will be transfused to maintain target Hb of ⩾8 g/dl. Patients will be started on IV Proton Pump Inhibitor, with bolus dose of terlipressin (2mg) followed by Endoscopic variceal ligation. All patients will received prophylactic antibiotics; antibiotics will be stopped if there will no other indication to continue. After confirmation of EVB (Esophageal Variceal Bleeding) and successful initial hemostasis with emergency EVBL (Endoscopic Variceal Band ligation), patients will be randomly assigned into Group -A (Bolus terlipressin at 2mg every 4hourly) and Group-B (Continuous infusion of terlipressin @ 4mg/24hour initially) therapy for esophageal varices . They will then undergo HVPG (Hepatic Venous Pressure Gradient) measurement at baseline, 12hours and 24hours. Patient in continuous group will titrate dose. accordingly to HVPG (Hepatic Venous Pressure Gradient) measurement at 12 and 24 hours. At 24 hours patient will be directed to receive either TIPS (Transjugular Intrahepatic Portosystemic Shunt) or will continue Terlipressin for 48 hours.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Mar 1, 2016
Study start
May 5, 2016
Primary completion
Dec 10, 2017
Study completion
Jan 31, 2018
Results posted
Not reported
Registry updated
Sep 4, 2019
Outcomes
What the study measures.
Primary outcomes
Reduction of HVPG (hepatic venous pressure gradient) at 24 hours >10%
Time frame · 24 hours
Secondary outcomes
Death in both groups
Time frame · 42 days
Terlipressin related complications in both groups
Time frame · 72 hours
Rebleed within 42 days
Time frame · 42 days
number of blood transfusion requirement at 5 days
Time frame · 5 days
Incidence of ischaemic hepatitis within 5 days
Time frame · 5 days
Incidence of post bleed acute kidney injury within 5 days
Time frame · 5 days
Incidence of post EVL(endoscopic band ligation) ulcer bleed within 5 days
Time frame · 5 days
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Any patient with only acute esophageal variceal bleeding (as defined by Asian pacific Association for the study of Liver Disease) * Informed consent to participate in the study * Age 18 to 70 years Exclusion Criteria: * Pregnant and lactation * Prior treatment with any vasoactive drugs * Significant heart or respiratory failure * Peripheral arteriopathy clinically significant * Previous heart stroke or significant alteration of the Electrocardiogram * Hemodynamically unstable * Refusal to participate in the study * Hypertension
Study locations
1 registered sites.
India. Showing up to 24 locations stored in the fast local snapshot.
Institute of liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Related trials
More studies on Terlipressin.
Intraoperative Continuous Terlipressin Infusion is Associated With Reduced Severe Postoperative Complications After Laparoscopic Hepatectomy: a Prospective Propensity Score-matched Cohort Study
First Affiliated Hospital, Sun Yat-Sen University · Liver Neoplasms · Postoperative Complications
Not applicable
Completed
161
2026-07
Efficacy Of Bovine Colostrum In The Treatment Of Severe Alcohol-Associated Hepatitis: A Randomized Controlled Trial
Dayanand Medical College and Hospital · Alcoholic Hepatitis
Phase 3
Active, not recruiting
174
2026-07
Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation
Beijing Friendship Hospital · Kidney Transplant · Delayed Graft Function
Not applicable
Active, not recruiting
150
2026-07
Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy
University Hospital, Rouen · Bronchial Endoscopy
Phase 3
Completed
130
2026-06
Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation
Istanbul Medipol University Hospital · Liver Transplantation · Portal Hypertension
Not applicable
Recruiting
50
2026-04
ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.
Assistance Publique - Hôpitaux de Paris · Hemoptysis
Phase 3
Completed
315
2026-04
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Noorik Biopharmaceuticals AG · Hepatorenal Syndrome · Liver Cirrhosis
Phase 2
Active, not recruiting
54
2026-04
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Institute of Liver and Biliary Sciences, India · Acute-on-Chronic Liver Failure (ACLF)
Not applicable
Not yet recruiting
56
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.